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ROLE OF c-MET AND EGFR IN ACQUIRED RESISTANCE TO PARP 
INHIBITORS IN TRIPLE-NEGATIVE BREAST CANCER 
 Clinton Yam, M.D. 
Advisory Professor: Jeffrey Chang, Ph.D. 
Triple-negative breast cancer is associated with a poor prognosis and 
treatment options are limited. The Poly (ADP-ribose) polymerase (PARP) inhibitors, 
olaparib and talazoparib, were recently approved for metastatic breast cancer 
(including triple-negative breast cancer) in patients with a germline BRCA1/2 
mutation. Despite impressive response rates of ~60%, the prolongation in median 
progression-free survival with PARP inhibitors is modest, suggesting the emergence 
of resistance. We previously demonstrated that c-MET contributes to intrinsic 
resistance to PARP inhibitors in triple-negative breast cancer. However, whether c-
MET plays a role in acquired resistance to PARP inhibitors in triple-negative breast 
cancer remains unclear. Here, we show that phospho-c-MET expression is higher in 
PARP inhibitor-resistant triple-negative breast cancer cells and the combination of 
talazoparib and crizotinib (multi-kinase inhibitor that inhibits c-MET) results in 
synergistic inhibition of cellular proliferation in PARP inhibitor -resistant cells. 
However, depleting c-MET in PARP inhibitor resistant cells had limited effect on 
talazoparib sensitivity. Notably, we found that c-MET interacts with the epidermal 
growth factor receptor (EGFR) in PARP inhibitor-resistant triple-negative breast 
cancer cells, potentially explaining the limited effect of c -MET depletion alone on 
talazoparib sensitivity. Together, these data suggest that the combination of c-MET, 
EGFR and PARP inhibition should be explored in future studies.
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CHAPTER 1. INTRODUCTION 
1.1 Triple-negative breast cancer  
Triple-negative breast cancers are defined by the lack of expression of three major 
actionable targets in breast cancer, namely, the estrogen receptor (ER), the progesterone 
receptor (PR), and the human epidermal growth factor receptor 2 (HER2) (1). Together, this 
subtype of breast cancer makes up 10-20% of primary breast cancers (2-5). In contrast with 
hormone receptor-positive and/or HER2-positive breast cancers, triple-negative breast cancers 
tend to be larger, more likely node-positive and of higher grade (6). Although triple-negative 
breast cancers are more likely to respond to cytotoxic chemotherapy in the neoadjuvant setting 
compared to other breast cancer subtypes, chemotherapy-resistant triple-negative breast cancer 
carries a dismal prognosis with a 40-80% risk of disease recurrence in the first 2-3 years 
following definitive surgical intervention (6-9). 
1.2 Triple-negative breast cancer and the DNA damage response pathway 
Seventy-one percent of breast cancers diagnosed in BRCA1 mutation carriers and 25% 
of breast cancers diagnosed in BRCA2 mutation carriers are triple-negative breast cancers. In 
contrast, only 17% of breast cancers diagnosed in non-BRCA1/2 mutation carriers were triple-
negative breast cancers (10). On average, 35% of patients with triple-negative breast cancer 
carry a germline BRCA1 mutation and 8% of patients with triple-negative breast cancer carry 
a BRCA2 mutation. BRCA1/2 mutations result in defective homologous recombination, leading 
to accumulation of DNA damage (11), increasing the sensitivity of such tumors to DNA 
damaging agents such as platinum agents and poly-ADP-ribose polymerase (PARP) inhibitors 
(12). In addition, some BRCA1/2-wild type triple-negative breast cancers have defective 
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homologous recombination and share the increased sensitivity to DNA damaging agents 
observed in BRCA1/2 mutant tumors, a phenotype commonly termed, BRCAness (12). 
1.3 Targeted therapy in triple-negative breast cancer 
Cytotoxic chemotherapy remained the only FDA-approved treatment for triple-
negative breast cancer up until recently, when two randomized phase III clinical trials (13, 14) 
led to the approval of olaparib and talazoparib for patients with metastatic or advanced, HER2-
negative breast cancer with a germline BRCA1/2 mutation, including those with triple-negative 
breast cancer. The overall response rate to olaparib in the phase III OlympiAD trial in patients 
with measureable disease was 59.9%, compared to 28.8% in patients receiving standard 
therapy (13). Median progression-free survival in patients receiving olaparib was 7.0 months, 
versus 4.2 months in patients receiving standard therapy (13). In the phase III EMBRACA 
study, the response rate to talazoparib was 62.6%, compared to 27.2% in patients receiving 
standard therapy (14). The median progression-free survival was 8.6 months in patients 
receiving talazoparib and 5.6 months in patients receiving standard therapy (14). Thus, 
although response rates to PARP inhibitors in advanced or metastatic breast cancer are 
impressive, the 3-month improvement in progression-free survival is modest, suggesting the 
emergence of resistance to these novel agents. 
1.4 Mechanisms of resistance to PARP inhibitors 
Several described mechanisms of resistance to PARP inhibitors have contributed to the 
current paradigm. First, restoration of homologous recombination through reversion mutations 
in BRCA1/2 (15) as well as concurrent mutations in TP53BP1 (16) or PTEN (17) have been 
shown to contribute to PARP inhibitor resistance. Second, increased reliance on alternate 
means of DNA repair like non homologous end joining can limit the therapeutic efficacy of 
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PARP inhibitors (18). Third, since PARP inhibitors suppress DNA repair at replication forks 
and promote formation of double strand breaks (19, 20), stabilization of the replication fork 
can antagonize the anti-tumor effects of PARP inhibitors (21-23). Fourth, reduced PARP 
expression (24) or binding (25) has been shown to result in PARP inhibitor resistance as did 
increased expression of PARP inhibitor efflux pumps (26). Fifth, cell cycle checkpoint 
activation has been reported to result in cell cycle delay, giving the cancer cell time to repair 
damaged DNA (27), resulting in resistance to PARP inhibition. Notably, inhibition of cyclin-
dependent kinase 12 (CDK12) was found to enhance sensitivity to PARP inhibitors (28-31). 
Additionally, increased WEE1 expression, which promotes cell cycle arrest and DNA repair, 
was found to result in PARP inhibitor resistance (32). Similarly, CHK1 has been shown to 
induce cell cycle arrest in response to DNA damage (33) and CHK1 inhibition has been shown 
to potentiate the effects of PARP inhibitors (34). 
1.5 Receptor tyrosine kinases in PARP inhibitor resistance 
In addition to the above described mechanisms of resistance to PARP inhibitors, the 
receptor tyrosine kinase c-MET has been shown to interact with and phosphorylate PARP1 at 
the Tyr907 residue, increasing its enzymatic activity and decreasing its binding to PARP 
inhibitors (35). Notably, in a model of intrinsic resistance to PARP inhibitors, the combination 
of a c-MET inhibitor and PARP inhibitor was shown to reduce proliferation of triple-negative 
breast cancer in vitro and in vivo (35). Interestingly, the epidermal growth factor receptor 
(EGFR), another receptor tyrosine kinase, has also been shown to interact with c-MET, leading 
to phosphorylation of PARP1 at the Tyr907 residue, contributing to PARP inhibitor-resistance 
in hepatocellular carcinoma (36). In triple-negative breast cancer, dual targeting of MET and 
EGFR was shown to inhibit tumor growth in a more consistent manner compared to inhibiting 
 
4 
 
either target alone (37) but the impact of c-MET and EGFR crosstalk signaling on PARP 
inhibitor resistance in triple-negative breast cancer remains unknown. 
1.5 Acquired resistance to PARP inhibitors and receptor tyrosine kinases 
While c-MET activity has been shown to enhance intrinsic resistance to PARP 
inhibitors in BRCA1/2 wild type triple-negative breast cancer (35), its role in acquired 
resistance to PARP inhibitors in BRCA1/2 deficient triple-negative breast cancer remains 
unclear. In addition, since coexpression of receptor tyrosine kinases has been shown to 
contribute to therapeutic resistance (37), significant involvement of other receptor tyrosine 
kinases in the setting of acquired resistance to PARP inhibitors remains a distinct possibility 
and an open question.  
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CHAPTER 2. MATERIALS AND METHODS 
2.1 Cell Culture 
 The SUM149 cell line was obtained from Asterand Biosciences (Detroit, MI) and 
maintained in F12K medium containing 5% FBS, 10 mM HEPES, 1mg/ml hydrocortisone, 5 
µg/ml insulin, 100 units/ml penicillin, and 100mg/ml streptomycin. The SUM149 cell line was 
validated by STR DNA fingerprinting using the AmpF_STR identifier kit following the 
manufacturer’s protocol (Applied Biosystems cat 4322288). The STR profiles were compared 
to ATCC fingerprints (ATCC.org) and the Cell Line Integrated Molecular Authentication 
(CLIMA) database version 0.1.200808 (http://bioinformatics.istge.it/clima/)  (38) . The PARP 
inhibitor-resistant triple-negative breast cancer cell lines, B3 and C12, were obtained from MK 
Chen and cultured as per SUM149. 
2.2  Immunoblotting 
 Whole cell lysates were prepared in radioimmunoprecipitation (RIPA) buffer (20 mM 
Tris-HCl, pH 7.5, 150 mM NaCl, 1mM  Na2EDTA, 1mM EGTA, 1% NP-40, 1% sodium 
deoxycholate,  2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1mM  Na3VO4 , 1 
µg/ml leupetin) with protease inhibitors (bimake.com) and phosphatase inhibitors 
(biotool.com). The concentration of protein in whole cell lysates was determined using the 
Pierce BCA protein assay kit (Fisher PI-23227) according to the manufacturer’s protocol. 10-
40 µg of protein from each sample was separated in an 8% Bis-Tris SDS PAGE gel and 
transferred to a polyvinylidene difluoride (PVDF) membrane (Life Technologies). After 
blocking with 5% bovine serum albumin (BSA), primary antibodies were incubated with the 
PVDF membranes overnight at 4°C. Membranes were washed in TBST (50 mM Tris-Cl, pH 
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7.5, 150 mM NaCl, 0.05% Tween-20) and hybridized with appropriate secondary antibodies 
for 45 minutes at room temperature and imaged using ECL reagents (Bio-Rad Laboratories). 
2.3 Immunoprecipitation  
 Whole cell lysates were prepared in immunoprecipitation buffer (25 mM Tris, pH 7.4; 
150 mM NaCl, 0.1% NP-40, 1 mM EDTA, 10% glycerol) and incubated with 1 µg of primary 
antibody or IgG control antibody overnight at 4°C. Protein G-agarose beads were then added 
and incubated at 4°C for 1 hour prior to washing and detection by immunoblotting as described 
in the previous section. 
2.4 MTT assay 
 B3 cells (1250 cells/well) and C12 cells (750 cells/well) were seeded in a 96 well plate 
and incubated overnight. After 24 hours, cells were then treated with varying concentrations 
of talazoparib and/or crizotinib for 6 days. 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) was added into each well to achieve a final concentration 
of 0.5 µg/ml before formazan extraction with DMSO. The optical density at 590 nm in each 
well was measured and then normalized to untreated wells. The Chou-Talalay method (39) 
was used to calculate the combination index using the Compusyn software 
(http://www.combosyn.com). 
2.5 Plasmids and transfection 
 For knockdown of c-MET, the PARP inhibitor-resistant triple-negative breast cancer 
cell lines, B3 and C12, were transfected with pLKO-shRNA vector (Sigma-Aldrich, St. 
Louis, MO). shRNA sequences used in generating stable knockdown clones are as follows 
(5′ to 3′): 
 
7 
 
CCGGGTGTGTTGTATGGTCAATAACCTCGAGGTTATTGACCATACAACACACTTT
TTTG*; 
CCGGCCTTCAGAAGGTTGCTGAGTACTCGAGTACTCAGCAACCTTCTGAAGGTTT
TTG 
*Targeting the 3’ UTR:  
2.6 Chemicals and Antibodies 
 Olaparib and talazoparib were purchased from Selleck Chemical (Houston, TX), 
Crizotinib was purchased from LC laboratories. Antibodies against MET (#8198), phospho-
MET (#3077), EGFR (#4267) and IgG (#2729) were purchased from Cell Signaling 
Technology (Danvers, MA). Antibodies for EphA2 (sc-398832) and Lamin B (sc-365962) 
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The antibody for phospho-
EGFR (Ab5650) was purchased from Abcam (Cambridge, UK). The antibody against ErbB2 
(#OP15) and ALK (#ABN263) were purchased from Millipore Sigma (Burlington, MA). The 
antibody against PARP1 pY907 was obtained from China Medical University (Taichung, 
Taiwan) (35). 
2.7 BRCA1/2 mutated breast cancer tissue samples 
 Tissue samples from 19 patients with stage I-III breast cancer and a germline BRCA1/2 
mutation were obtained at baseline and at the time of surgery following treatment with 
talazoparib in the neoadjuvant setting. Reverse phase protein arrays (40) and whole exome 
sequencing were performed by the proteomics and sequencing core facility at The University 
of Texas MD Anderson Cancer Center, respectively. 
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CHAPTER 3. RESULTS 
3.1 Phospho-c-MET expression is higher in PARP inhibitor-resistant triple-negative 
breast cancer cells compared to PARP inhibitor-sensitive triple-negative breast cancer 
cells. 
  PARP inhibitor-resistant triple-negative breast cancer cell lines were created by 
treating a PARP inhibitor-sensitive triple-negative breast cancer cell line (SUM149) with 
increasing doses of the PARP inhibitor, talazoparib. 31 single clones demonstrating increased 
resistance to PARP inhibitors (elevated IC50) were selected. Among these 31 clones, we 
identified two PARP inhibitor-resistant triple-negative breast cancer cell lines (B3 and C12) 
which had significantly higher levels of phospho-c-MET expression relative to the parental 
PARP inhibitor-sensitive triple-negative breast cancer cell line (SUM149) under basal 
conditions as well as following 24 hours of exposure to either olaparib or talazoparib (Figure 
1). Total c-MET expression was also higher in the two PARP inhibitor-resistant triple-negative 
breast cancer cell lines (B3 and C12) compared to the parental PARP inhibitor-sensitive triple-
negative breast cancer cell line (SUM149), albeit to a lesser extent (Figure 1). Therefore, the 
extent of c-MET phosphorylation in the PARP inhibitor-resistant triple-negative breast cancer 
cell lines B3 and C12 is significantly greater compared to that of the parental PARP inhibitor 
sensitive triple-negative breast cancer cell line (SUM149), suggesting that c-MET may play a 
role in mediating acquired resistance to PARP inhibitors. 
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FIGURE 1. The PARP inhibitor-resistant triple-negative breast cancer cell lines B3 and 
C12 have higher levels of phospho-c-MET expression relative to the PARP inhibitor-
sensitive parental triple-negative breast cancer cell line, SUM149 (parental). Cells were 
treated with vehicle control (con), olaparib (ola) at a concentration of 0.5 µM or 1.0 µM, or 
talazoparib (Tala) at a concentration of 25 nM for 24 hours prior to preparation of whole cell 
lysates. Immunoblotting was used to determine relative levels of phospho-c-MET, total c-MET 
and lamin B expression. 
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FIGURE 1. 
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3.2 Combining crizotinib with talazoparib results in synergistic inhibition of cellular 
proliferation in PARP inhibitor-resistant triple-negative breast cancer cell lines. 
 The PARP inhibitor-resistant triple-negative breast cancer cell lines B3 and C12 were 
treated with varying concentrations of crizotinib, a multi-kinase inhibitor that inhibits c-MET, 
and talazoparib, a PARP inhibitor (Table 1). Using the combination index theorem of Chou-
Talalay (39), the combination index for crizotinib and talazoparib was calculated. In both 
PARP inhibitor-resistant triple-negative breast cancer cell lines B3 and C12, the combination 
index for crizotinib and talazoparib was <1 at a wide range of concentrations, suggesting 
synergistic inhibition of cellular proliferation (Figure 2). 
 
3.3 Depleting c-MET in PARP inhibitor-resistant triple-negative breast cancer cells has 
limited impact on restoring sensitivity to talazoparib. 
 To specifically assess the role of c-MET in acquired resistance to PARP inhibitors in 
triple-negative breast cancer, we depleted c-MET in two PARP inhibitor-resistant triple-
negative breast cancer cell lines (B3 and C12) with significantly higher levels of phospho-c-
MET expression relative to parental PARP inhibitor-sensitive triple-negative breast cancer 
cells using two independent short hairpin RNAs (shRNAs) which we delivered via a lentiviral 
system. (Figure 3). Knockdown efficiency of >50% was achieved in all cases (Figure 4). We 
then treated the c-MET depleted PARP inhibitor-resistant triple-negative breast cancer cell 
lines and c-MET expressing (vector control) PARP inhibitor-resistant triple-negative breast 
cancer cell lines with varying concentrations of talazoparib. Depleting c-MET in the PARP 
inhibitor-resistant triple-negative breast cancer cell line, C12, modestly increased sensitivity 
to talazoparib (Figure 5) whereas depleting c-MET in the PARP inhibitor-resistant triple-
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negative breast cancer cell line, B3, did not consistently increase sensitivity to talazoparib 
(Figure 6). 
 
 
13 
 
TABLE 1. A table showing the concentrations (in nM) of crizotinib and talazoparib used 
in the determination of the combination index for the PARP inhibitor-resistant triple-
negative breast cancer cell lines, B3 and C12. 
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TABLE 1. 
nM Crizotinib 250 500 1000 2000 4000 
Talazoparib 0                             0 0                        250 0                        500 0                        1000 0                        2000 0                        4000 
62.5 62.5                        0 62.5                        250 62.5                        500 62.5                       1000 62.5                       2000 62.5                       4000 
125 125                         0 125                        250 125                        500 125                        1000 125                        2000 125                        4000 
250 250                         0 250                        250 250                        500 250                        1000 250                        2000 250                        4000 
500 500                         0 500                       250 500                        500 500                        1000 500                        2000 500                        4000 
1000 1000                        0 1000                        250 1000                        500 1000                    1000 1000                    2000 1000                     4000 
 
 
15 
 
FIGURE 2. The combination of crizotinib and talazoparib results in synergistic 
inhibition of cellular proliferation in PARP inhibitor-resistant triple-negative breast 
cancer cell lines, B3 and C12. The PARP inhibitor-resistant triple-negative breast cancer cell 
lines, B3 and C12, were treated with varying concentrations of crizotinib and talazoparib for 6 
days. Following 6 days of treatment, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay was performed. The combination index (CI) was calculated and 
synergistic inhibition of cellular proliferation was defined as a CI <1. 
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FIGURE 2. 
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FIGURE 3. PARP inhibitor-resistant triple-negative breast cancer cell lines were 
infected with lentiviral particles carrying non-specific or c-MET-targeting short harpin 
RNA (shRNAs) sequences. 
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FIGURE 3. 
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FIGURE 4. Following lentiviral delivery of two independent short harpin RNAs targeting 
c-MET to PARP inhibitor-resistant triple-negative breast cancer cell lines, B3 and C12, 
expression levels of c-MET was reduced by at least 50% relative to cells receiving non-
specific short hairpin RNA (shRNA) sequences. The PARP inhibitor-resistant triple-
negative breast cancer cell lines, B3 and C12, were infected with control shRNA (control), an 
shRNA targeting the 3’ UTR of c-MET (sh-c-MET-1), or an shRNA targeting the coding 
region of c-MET (sh-c-MET-2). Relative expression levels of total c-MET in stable clones 
were determined by immunoblotting. 
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FIGURE 4. 
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FIGURE 5. Depleting c-MET results in a modest increase in sensitivity to talazoparib in 
the PARP inhibitor-resistant triple-negative breast cancer cell line C12. 750 cells were 
seeded in each well of a 96-well plate on Day 0. On Day 1, talazoparib was added at varying 
concentrations to each well (12.5-200 nM). Following 6 days of treatment, the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed and the 
percentage of surviving cells in each well was calculated. Depicted values represent the mean 
of biological and technical triplicates. 
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FIGURE 5. 
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FIGURE 6. Depleting c-MET in the PARP inhibitor resistant triple-negative breast 
cancer cell line B3 does not consistently increase sensitivity to talazoparib. 1500 cells were 
seeded in each well of a 96-well plate on Day 0. On Day 1, talazoparib was added at varying 
concentrations to each well (125-2000 nM). Following 6 days of treatment, the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed and the 
percentage of surviving cells in each well was calculated. Depicted values represent the mean 
of biological and technical triplicates. 
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FIGURE 6. 
 
25 
 
3.4 c-MET interacts with EGFR in PARP inhibitor-resistant triple-negative breast 
cancer cell lines. 
 Since c-MET is known to interact with multiple cell surface molecules (41), including 
receptor tyrosine kinases like EGFR (41), we evaluated expression data derived from a 
phospho-receptor tyrosine kinase array comparing expression levels of a series of phospho-
receptor tyrosine kinases in the PARP inhibitor-resistant triple-negative breast cancer cell line, 
C12, to that in the PARP inhibitor-sensitive parental triple-negative breast cancer cell line, 
SUM149 (data not shown). Following exposure to talazoparib, the phospho-c-MET 
overexpressing PARP inhibitor-resistant triple-negative breast cancer cell line, C12, was found 
to have higher expression levels of phospho-EGFR, phospho-ErbB2, phospho-ALK, and 
phospho-EPHA2 relative to the PARP inhibitor-sensitive parental triple-negative breast cancer 
cell line, SUM149 (data not shown). We therefore hypothesized that the modest effect of c-
MET depletion on talazoparib sensitivity in PARP inhibitor-resistant triple-negative breast 
cancer cell lines could be the result of protein-protein interactions involving c-MET and other 
receptor tyrosine kinases. To identify potential c-MET interacting receptor tyrosine kinases, 
we immunoprecipitated c-MET, and found enhanced interaction between c-MET and EGFR 
in the PARP inhibitor-resistant triple-negative breast cancer cell line, C12, relative to the PARP 
inhibitor-sensitive parental triple-negative breast cancer cell line, SUM149 (Figure 7). In 
contrast, ErbB2 (Figure 7), ALK (Figure 8) and EphA2 (Figure 8) were not identified as 
interacting proteins of c-MET. We then immunoprecipitated c-MET in whole cell lysates 
obtained from the PARP inhibitor-resistant triple-negative breast cancer cell lines, B3 and C12, 
as well as PARP inhibitor-sensitive triple-negative breast cancer cell line (SUM149) under 
basal conditions and following treatment with talazoparib. The results showed that the 
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interaction between c-MET and EGFR was enhanced in the PARP inhibitor-resistant cells 
relative to the PARP inhibitor-sensitive parental cells under basal conditions as well as 
following treatment with talazoparib (Figure 9). In addition, expression of phospho- and total-
EGFR was significantly higher in PARP inhibitor-resistant triple-negative breast cancer cell 
lines, B3 and C12, compared to the PARP inhibitor-sensitive parental triple-negative breast 
cancer cell line, SUM149, under basal conditions as well as following 24 hours of treatment 
with olaparib or talazoparib (Figure 10). Collectively, these data suggest that EGFR may 
cooperate with c-MET in mediating resistance to PARP inhibitors through direct interaction. 
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FIGURE 7. Enhanced interaction between c-MET and EGFR but not ErbB2 is detected 
in the PARP inhibitor-resistant triple-negative breast cancer cell line, C12, relative to 
PARP inhibitor-sensitive parental (PT) triple-negative breast cancer cell line (SUM149), 
following treatment with talazoparib. Parental (PT) cells and resistant cell (C12) were 
treated with talazoparib (Tala) at a concentration of 25 nM for 24 hours prior to preparation of 
whole cell lysates. Anti-cMET or IgG control antibodies were used to immunoprecipitate the 
cell lysate. EGFR and ErbB2 expression was then analyzed by immunoblotting. 
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FIGURE 7. 
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FIGURE 8. Interaction between c-MET and ALK or EphA2 was not enhanced in the 
PARP inhibitor-resistant triple-negative breast cancer cell, C12, relative to PARP 
inhibitor-sensitive parental (PT) triple-negative breast cancer cells (SUM149), following 
treatment with talazoparib. Parental (PT) cells and resistant cell (C12) were treated with 
talazoparib (Tala) at a concentration of 25 nM for 24 hours prior to preparation of whole cell 
lysates. Anti-cMET or IgG control antibodies were used to immunoprecipitate the cell lysate. 
ALK and EphA2 expression was then analyzed by immunoblotting. 
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FIGURE 8 
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FIGURE 9. The interaction between c-MET and EGFR is enhanced in PARP inhibitor-
resistant triple-negative breast cancer cells (B3 and C12) relative to PARP inhibitor-
sensitive parental (PT) triple-negative breast cancer cells (SUM149), under basal 
conditions as well as following treatment with talazoparib. Parental (PT) cells and resistant 
cells (B3 and C12) were treated with vehicle control (Con) or talazoparib (Tala) at a 
concentration of 25 nM for 24 hours prior to preparation of whole cell lysates. Anti-cMET or 
IgG control antibodies were used to immunoprecipitate the cell lysate. EGFR expression was 
then analyzed by immunoblotting. 
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FIGURE 9 
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FIGURE 10.  The PARP inhibitor-resistant triple-negative breast cancer cell lines B3 and 
C12 have higher levels of phospho- and total-EGFR expression relative to the PARP 
inhibitor-sensitive parental triple-negative breast cancer cell line, SUM149. Cells were 
treated with vehicle control, olaparib at a concentration of 0.5 µM or 1.0 µM, or talazoparib at 
a concentration of 25 nM for 24 hours prior to preparation of whole cell lysates. Relative 
expression levels of phospho- and total-EGFR were determined by immunoblotting. 
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FIGURE 10. 
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3.5 c-MET and EGFR/phospho-EGFR protein expression levels increase in patients with 
talazoparib-resistant breast cancer. 
  We identified 19 patients with previously untreated stage I-III breast cancer 
who received talazoparib in the neoadjuvant setting as part of a clinical trial conducted at The 
University of Texas MD Anderson Cancer Center (NCT02282345). Patients enrolled on this 
study underwent a pretreatment core needle biopsy at baseline and received up to 6 months of 
treatment with talazoparib before undergoing surgery to remove any residual cancer (Figure 
11). The amount of residual cancer was quantified using the residual cancer burden (RCB) 
index (42). Patients were classified as having talazoparib-sensitive disease if they had a 
pathologic complete response or minimal residual disease (pCR/RCB-I) and classified as 
having talazoparib-resistant disease if they had significant residual disease (RCB-II/RCB-III). 
Of the 19 patients, 4 patients had sufficient tissue for paired anaylsis. Among the 4 patients 
with paired tissue samples, 2 had talazoparib-sensitive disease and the remaining 2 had 
talazoparib-resistant disease. Following treatment with talazoparib, patients with talazoparib-
sensitive disease had a decrease in c-MET, EGFR and phospho-EGFR protein expression, 
whereas patients with talazoparib-resistant disease had an increase in c-MET, EGFR and 
phospho-EGFR protein expression (Figures 12-14), suggesting potential compensatory 
upregulation of these pathways in talazoparib-resistant breast cancer. 
 
3.6 Genomic alterations in c-MET and EGFR in patients treated with talazoparib 
 Whole exome sequencing was performed on baseline and surgical specimens obtained 
from the 19 patients with stage I-III breast cancer treated with talazoparib in the neoadjuvant 
setting. We did not identify any single nucleotide variants or indels in MET or EGFR in tumors 
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from this cohort of patients. Baseline MET copy number was similar in tumors from patients 
with talazoparib-sensitive and talazoparib-resistant disease (Figure 15). Among the 4 patients 
with paired samples, treatment with talazoparib increased MET copy number (Figure 15 but 
the greatest difference was observed in patients with talazoparib-resistant disease. 
Interestingly, patients who had talazoparib-sensitive disease appeared to have higher EGFR 
copy number compared to patients who had talazoparib-resistance disease at baseline (Figure 
16). Among the 4 patients with paired samples, treatment with talazoparib treatment with 
talazoparib increased EGFR copy number (Figure 16) but the greatest difference was observed 
in patients with talazoparib-resistant disease. 
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FIGURE 11. Study schema for NCT02282345. Patients with stage I-III breast cancer with a 
germline BRCA1 or BRCA2 mutation underwent a pretreatment core needle biopsy at baseline. 
Patients were then treated with up to 6 months of talazoparib prior to definitive surgery to 
remove any residual cancer. 
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FIGURE 11. 
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FIGURE 12. MET protein expression increased in patients with talazoparib-resistant 
breast cancer following treatment with single-agent talazoparib in the neoadjuvant 
setting. Patients with stage I-III breast cancer with a germline BRCA1/2 mutation were 
treated with talazoparib in the neoadjuvant setting prior to undergoing definitive surgery. 
Patients underwent a baseline core needle biopsy prior to initiating therapy. Reverse phase 
protein arrays were used to measure levels of MET expression in pre-treatment biopsy 
specimens and surgical specimens obtained at the end of treatment. 
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FIGURE 12. 
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FIGURE 13.  Patients with talazoparib-resistant breast cancer had an increase in EGFR 
expression following treatment with single-agent talazoparib in the neoadjuvant setting. 
Patients with stage I-III breast cancer with a germline BRCA1/2 mutation were treated with 
talazoparib in the neoadjuvant setting prior to undergoing definitive surgery. Patients 
underwent a baseline core needle biopsy prior to initiating therapy. Reverse phase protein 
arrays were used to measure levels of EGFR expression in pre-treatment biopsy specimens and 
surgical specimens obtained at the end of treatment. 
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FIGURE 13. 
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FIGURE 14.  Phospho-EGFR expression levels increased in patients with talazoparib-
resistant breast cancer following treatment with single-agent talazoparib in the 
neoadjuvant setting. Patients with stage I-III breast cancer with a germline BRCA1/2 mutation 
were treated with talazoparib in the neoadjuvant setting prior to undergoing definitive surgery. 
Patients underwent a baseline core needle biopsy prior to initiating therapy. Reverse phase 
protein arrays were used to measure levels of phospho-EGFR expression in pre-treatment 
biopsy specimens and surgical specimens obtained at the end of treatment. 
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FIGURE 14. 
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FIGURE 15. Patients with talazoparib-sensitive and talazoparib-resistant disease 
appeared to have similar MET copy number at baseline. Treatment with talazoparib 
increased MET gene copy number, with the greatest increase observed in patients with 
talazoparib-resistant disease. Patients with stage I-III breast cancer with a germline BRCA1/2 
mutation were treated with talazoparib in the neoadjuvant setting prior to undergoing definitive 
surgery. Patients underwent a baseline core needle biopsy prior to initiating therapy. Whole 
exome sequencing was used to determine gene copy numbers of MET in pre-treatment biopsy 
specimens and surgical specimens obtained at the end of treatment. 
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FIGURE 15. 
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FIGURE 16. Patients with talazoparib-sensitive disease had higher EGFR copy number 
at baseline. Treatment with talazoparib increased EGFR gene copy number, with the 
greatest increase observed in patients with talazoparib-resistant disease.  Patients with 
stage I-III breast cancer with a germline BRCA1/2 mutation were treated with talazoparib in 
the neoadjuvant setting prior to undergoing definitive surgery. Patients underwent a baseline 
core needle biopsy prior to initiating therapy. Whole exome sequencing was used to determine 
gene copy numbers of EGFR in pre-treatment biopsy specimens and surgical specimens 
obtained at the end of treatment. 
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FIGURE 16. 
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3.7 Phosphorylation of PARP1 is not observed consistently in phospho-c-MET 
overexpressing PARP inhibitor-resistant triple-negative breast cancer cell lines. 
 In a model of intrinsic resistance to PARP inhibitors in triple-negative breast cancer, it 
was previously demonstrated that oxidative stress increases phosphorylation of c-MET which 
in turn phosphorylates PARP1 at the Tyr907 residue (PARP1 pTyr907 or pY907) (35), 
increasing enzymatic activity of PARP1 and reducing PARP inhibitor binding (35) which leads 
to PARP inhibitor resistance. In addition, while preclinical studies in hepatocellular carcinoma 
revealed that oxidative damage led to increased PARP1 pY907 expression (36), inhibiting c-
MET activity with crizotinib did not consistently reduce PARP1 pY907 expression levels in 
hepatocellular carcinoma cell lines due to EGFR-mediated PARP1 phosphorylation (36). Thus, 
since we observed evidence of increased interaction between c-MET and EGFR in the c-MET 
overexpressing PARP inhibitor-resistant triple-negative breast cancer cell lines, B3 and C12, 
relative to the PARP inhibitor-sensitive parental triple-negative breast cancer cell line, 
SUM149, we hypothesized that c-MET and EGFR cooperate to augment resistance to PARP 
inhibitors through increased phosphorylation of PARP1 at the Tyr907 residue. However, while 
PARP1 pY907 levels were significantly higher in the PARP inhibitor-resistant triple-negative 
breast cancer cell line, C12, compared to the PARP inhibitor-sensitive parental triple-negative 
breast cancer cell line, SUM149, PARP1 Y907 levels were not significantly higher in the 
second c-MET overexpressing PARP inhibitor-resistant triple-negative breast cancer cell line, 
B3 (Figure 17). Together, these data suggest that increased PARP1 pY907 expression is 
unlikely to be the dominant mechanism contributing to acquired resistance to PARP inhibitors 
in c-MET overexpressing triple-negative breast cancer. 
 
50 
 
FIGURE 17. p-Y907 PARP1 expression is increased in resistant cells, C12 but not B3 
with PARPi treatment. PARP inhibitor-sensitive parental (PT) triple-negative breast cancer 
cells (SUM149) and PARP inhibitor-resistant triple-negative breast cancer cells (B3 and C12) 
were treated with vehicle control (Con), olaparib (Ola) at a concentration of 0.5 µM or 1.0 µM, 
or talazoparib (Tala) at a concentration of 25 nM for 24 hours prior to preparation of whole 
cell lysates. The cell lysates were then subjected to western blotting with the indicated 
antibodies. 
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FIGURE 17. 
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3.8 Interacting proteins of c-MET and EGFR are involved in DNA damage repair. 
Given the observed interaction between EGFR and c-MET in c-MET overexpressing 
PARP inhibitor-resistant triple-negative breast cancer cell lines we sought to identify potential 
mechanisms of acquired resistance to PARP inhibitors in this setting, we utilized BioGRID 
(https://thebiogrid.org) and identified 91 and 1254 proteins known to interact with c-MET and 
EGFR, respectively. Of these, 33 were found to interact with both c-MET and EGFR (Figure 
18, Table 2). Functional annotation of these 33 proteins using The Database for Annotation, 
Visualization and Integrated Discovery (DAVID) (https://david.ncifcrf.gov/) led to the 
identification of 6 proteins involved in DNA damage repair (Table 3).  
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FIGURE 18.  Systematic search of a public database (BioGRID) revealed 91 c-MET 
interacting and 1254 EGFR-interacting proteins. Of these, 33 were identified to interact 
with both c-MET and EGFR. 
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FIGURE 18. 
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TABLE 2. List of proteins known to interact with both c-MET and EGFR. 
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TABLE 2. 
 
 
List of binding proteins of c-MET and EGFR 
CBL CRK ERBB3 HGS INPPL1 MAP2K5 SFN SOS1 
CBLC CTNNB1 FBXO6 HSP90AA1 ITGB1 NF2 SH3KBP1 SRC 
CD44 DCN GAB1 HSP90AB1 LRIG1 PTEN SHC1 STAT3 
CDH1 EPHA2 GRB2 HSPA4 MAP2K3 RAF1 SOCS1 STUB1 
TP53        
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TABLE 3. List of proteins known to interact with both c-MET and EGFR that are 
involved in DNA damage repair. 
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TABLE 3. 
Protein/Gene Function 
FBXO6 DNA repair 
STUB1 DNA repair 
SFN Apoptotic response to DNA damage 
CDH1 DNA repair 
TP53 DNA damage response 
PTEN DNA damage repair 
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CHAPTER 4. DISCUSSION 
4.1 Significance and Conclusions 
 PARP inhibitors are the first targeted agents to receive FDA approval for the treatment 
of triple-negative breast cancer in the setting of germline BRCA1/2 mutations. However, 
despite having response rates greater than double that observed with standard therapy (13, 14), 
the modest prolongation of median progression-free survival (13, 14) suggests the emergence 
of resistance shortly after an initial response. We had previously described the role of the 
receptor tyrosine kinase, c-MET, in a model of intrinsic resistance to PARP inhibitors using in 
vitro and in vivo models recapitulating BRCA1/2 wild type triple-negative breast cancers (35). 
However, whether c-MET plays a role in acquired resistance to PARP inhibitors in BRCA1/2-
mutant triple-negative breast cancers is an unanswered question. In this study, we 
demonstrated that phospho-c-MET levels were higher in PARP inhibitor resistant triple-
negative breast cancer cell lines compared to the PARP inhibitor-sensitive parental triple-
negative breast cancer cell line. Notably, this difference in phospho-c-MET expression 
between PARP inhibitor-resistant triple-negative breast cancer cell lines and the PARP 
inhibitor-sensitive parental triple-negative breast cancer cell line was present under basal 
conditions as well as following treatment with olaparib or talazoparib. In contrast, oxidative 
stress was needed to induce phospho-c-MET expression in triple-negative breast cancer cell 
lines which were intrinsically resistant to PARP inhibitors (35).  However, although the 
combination of crizotinib and talazoparib resulted in synergistic inhibition of proliferation of 
PARP inhibitor-resistant triple-negative breast cancer cells, depleting c-MET in these PARP 
inhibitor-resistant triple-negative breast cancer cells did not consistently restore sensitivity to 
talazoparib. Given the increased expression of additional phosphorylated receptor tyrosine 
 
60 
 
kinases in the PARP inhibitor-resistant triple-negative breast cancer cell lines and our previous 
work showing that EGFR interacts with c-MET to enhance resistance to PARP inhibitors in 
hepatocellular carcinoma (36) as well as the existence of crosstalk between c-MET and EGFR 
in triple-negative breast cancer (37), we systematically evaluated the existence of c-MET 
interacting receptor tyrosine kinases in the PARP inhibitor-resistant triple-negative breast 
cancer cell lines and identified EGFR as an interacting protein of c-MET in PARP inhibitor-
resistant triple negative breast cancer cell lines. Notably, the observed interaction between 
EGFR and c-MET remained relatively consistent under both basal conditions and following 
treatment with talazoparib in the PARP inhibitor-resistant triple-negative breast cancer cell 
line, C12, but seemed to be diminished following treatment with talazoparib in the PARP-
inhibitor resistant triple-negative breast cancer cell line, B3. Notably, levels of phospho-c-
MET and phospho-EGFR expression in the PARP inhibitor resistant triple-negative breast 
cancer cell line, B3, were also diminished following treatment with talazoparib, potentially 
explaining the reduced interaction between c-MET and EGFR, a finding consistent with earlier 
data from our laboratory demonstrating that phosphorylation of c-MET and EGFR promotes 
their interaction (36). Of note, resistance to PARP inhibitors in hepatocellular carcinoma has 
been reported to be enhanced by phosphorylation of PARP1 by EGFR/MET heterodimers 
following oxidative DNA damage (36). In addition, inhibitors of receptor tyrosine kinases have 
been reported to inhibit nuclear translocation of EGFR (43) which may be necessary for 
EGFR/MET mediated phosphorylation of PARP1, a nuclear protein. Together, these data 
suggest that the interaction between EGFR and c-MET contribute to acquired resistance to 
PARP inhibitors in triple-negative breast cancer and combined inhibition of EGFR, c-MET 
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and PARP may overcome therapeutic resistance and inhibit malignant proliferation of triple-
negative breast cancer. 
4.2 Clinical Implications 
 The identification of EGFR as an interacting protein of c-MET in PARP inhibitor-
resistant triple-negative breast cancer cell lines suggests that dual inhibition of c-MET and 
EGFR may be required to restore sensitivity to PARP inhibitors in the setting of receptor 
tyrosine kinase-mediated resistance. In addition, since phospho-c-MET and phospho-EGFR 
levels were significantly elevated in PARP inhibitor-resistant triple-negative breast cancer cell 
lines compared to PARP inhibitor-sensitive triple-negative breast cancer cell lines, phospho-
c-MET and phospho-EGFR could serve as potential biomarkers to identify patients likely to 
benefit from this combinatorial treatment strategy following development of resistance to 
PARP inhibitors. 
4.3 Future Directions 
 While our data suggest that the interaction between EGFR and c-MET is likely to 
contribute to acquired resistance to PARP inhibitors in triple-negative breast cancer. The 
mechanism underlying this observation remains unknown and should be explored in future 
studies. Through a systematic search of online databases, we identified 6 proteins known to 
interact with both EGFR and c-MET that were known to play a role in DNA repair. 
 FBXO6 is an F box protein that is known to promote replication stress-induced Chk1 
degradation. Low levels of FBXO6 has been associated with impairment of Chk1 degradation, 
leading to replication fork stabilization and activation of DNA repair responses, resulting in 
resistance to PARP inhibitors through an increased Chk1-mediated DNA damage repair (44). 
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 STUB1 encodes an E3 ubiquitin-protein ligase CHIP which has been shown to 
ubiquitylate and degrade base excision repair proteins that are not part of the DNA repair 
complex, resulting in greater efficiency of base excision repair (45) which may in turn lead to 
resistance to PARP inhibitors. 
 SFN encodes the protein 14-3-3 sigma which increases non-homologous end joining 
and upregulates PARP1 expression, enhancing DNA repair (46) and potentially contributing 
to PARP inhibitor resistance. 
 CDH1 binds to and activates the anaphase promoting complex or cyclosome (APC/C) 
which degrades Plk1 in response to DNA damage and prevents cell cycle progression past G2 
in cells with DNA damage (47). Additionally, depleting CDH1 impairs Chk1 phosphorylation 
which may also reduce a cell’s ability to repair damaged DNA (47). Thus, since CDH1 
contributes maintaining genomic integrity in cells, its activation may limit sensitivity to PARP 
inhibitors. 
 TP53 plays a crucial role in maintaining genomic stability (48) and it is plausible that 
EGFR and/or c-MET may, through its interaction with p53, promote its ability to prevent 
catastrophic DNA damage, inducing resistance to PARP inhibitors. 
 PTEN was recently demonstrated to promote repair of double strand DNA breaks via 
homologous recombination and loss of PTEN improved sensitivity to PARP inhibitors (49). 
Thus, whether EGFR and/or c-MET promotes PARP inhibitor resistance by enhancing PTEN 
activity remains an open question. 
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